Michael Gomes, a promising PhD candidate at the University of the Witwatersrand (Wits), has secured a prestigious scholarship that could transform the fight against one of the deadliest forms of brain cancer. His work at the Wits Advanced Drug Delivery Platform (WADDP) centers on developing nanoparticle-based systems for targeted drug delivery to glioblastoma tumors, addressing longstanding barriers in treatment efficacy. This breakthrough comes at a critical time for South African higher education and medical research, where clinician-scientists like Gomes are bridging the gap between laboratory innovation and clinical application.
Glioblastoma multiforme (GBM), the most common and aggressive primary brain tumor in adults, arises from glial cells that support neurons. Characterized by rapid growth, infiltration into surrounding brain tissue, and resistance to therapy, GBM poses immense challenges. Globally, patients face a median survival of just 12 to 18 months post-diagnosis, even with aggressive multimodal treatment involving maximal safe surgical resection, radiation, and temozolomide chemotherapy. In South Africa, outcomes are often worse due to factors like delayed diagnosis, limited access to neurosurgical expertise, and prohibitive treatment costs, exacerbating health inequities in low- and middle-income settings.
The Formidable Foe: Understanding Glioblastoma and Its Treatment Hurdles
Glioblastoma's lethality stems from multiple biological hallmarks. These tumors exhibit genetic instability, hypoxia-induced necrosis, neo-angiogenesis, and evasion of apoptosis, making complete eradication nearly impossible. Surgery removes the bulk but leaves microscopic cells behind, while radiation and chemotherapy struggle with delivery issues.
The blood-brain barrier (BBB)—a tightly regulated endothelial layer shielding the brain from toxins—blocks over 98% of small-molecule drugs and nearly all large therapeutics from reaching tumors at therapeutic concentrations. This selective permeability, essential for neuronal protection, becomes a therapeutic obstacle, leading to sub-optimal dosing, resistance development, and severe systemic side effects like nausea, myelosuppression, and neurotoxicity.
In South Africa, age-standardized mortality rates for brain cancer hover around 2.34-2.62 per 100,000 for women, with trends showing increases, while global incidence stands at 4.8 per 100,000 for males and 3.6 for females. Sub-Saharan Africa's rising cancer mortality—up 45% since 2000—underscores the urgency for localized innovations.
Wits Advanced Drug Delivery Platform: A Hub for Nanomedicine Innovation
Established in 2007 at Wits University, the WADDP, directed by Professor Yahya Choonara, is a flagship research unit pioneering advanced drug delivery systems. It integrates nanotechnology, polymer science, and clinical collaboration to tackle unmet needs in oncology, neurology, and infectious diseases. WADDP's interdisciplinary approach includes fabricating nanoscale carriers, simulating tumor microenvironments, and partnering with neurosurgeons for translational models.
The platform's recent advances, like siRNA nanoparticles penetrating the intact BBB, highlight its prowess in brain-targeted therapies. For aspiring researchers, WADDP offers cutting-edge facilities and mentorship, positioning Wits as a leader in South African higher education's push for impactful science. Explore research jobs at platforms like WADDP to join such initiatives.
Meet Michael Gomes: The Clinician-Scientist Driving Change
Michael Gomes embodies the next generation of South African medical researchers. Enrolled in Wits' intercalated PhD program—allowing simultaneous medical training and doctoral research—he balances clinical exposure with rigorous science. Aiming for neurosurgery specialization, Gomes brings patient-centered insights to his lab work, understanding real-world complexities like resource constraints in public hospitals.
"One of the biggest challenges in treating brain tumours is simply getting the drug to where it needs to be," Gomes notes, emphasizing the BBB's role. His passion stems from witnessing glioblastoma's toll, fueling a quest for therapies that extend survival and quality of life.
The Game-Changing SAMRC Clinician-Researcher Scholarship
The 2026 South African Medical Research Council (SAMRC) Institutional Clinician Researcher Development Programme scholarship is a competitive national award supporting PhD-trained clinicians. It fosters a cadre of scientist-physicians to translate discoveries into practice, addressing South Africa's clinician-scientist shortage. For Gomes, it provides crucial funding to advance his nanoparticle project while continuing medical studies.
This program aligns with national priorities in health research capacity-building. Aspiring scholars can find opportunities via scholarships and postdoc positions listed on AcademicJobs.com.
Photo by National Cancer Institute on Unsplash
Decoding the Research: Nanoparticles and the Glymphatic Pathway
Gomes's project systematically compares three nanoparticle platforms:
- Liposomes: Lipid vesicles encapsulating drugs, FDA-approved for various cancers, offering biocompatibility but limited stability.
- Polymer-based nanoparticles (e.g., PLGA): Biodegradable poly(lactic-co-glycolic acid) particles enabling controlled, stimuli-responsive release (pH, enzymes in tumor milieu).
- Polydopamine nanoparticles: Novel, dopamine-mimetic coatings providing adhesion to tumor cells, photothermal effects, and brain biocompatibility for reduced immunogenicity.
A standout innovation: Leveraging the glymphatic system—a perivascular network flushing cerebrospinal fluid (CSF) through brain parenchyma for waste clearance, most active during sleep. By intrathecal (CSF) injection, nanoparticles bypass the BBB, exploiting glymphatic flow to perfuse tumors homogeneously, boosting local drug levels 5-10 fold while sparing healthy tissue.
Step-by-step process: 1) Synthesize/functionalize nanoparticles with tumor-homing ligands (e.g., transferrin for overexpressed receptors); 2) Load chemotherapeutics like temozolomide; 3) Characterize size (<200nm for glymphatic penetration), zeta potential, release kinetics; 4) Validate in 3D brain tumor organoids and rodent GBM models; 5) Assess efficacy via MRI, survival, histopathology.
Recent global advances validate this: 2025 studies show monocyte-coated nanoparticles targeting GBM vasculature, magnetic nanoparticles for hyperthermia, and hydrogel NPs for sustained release.
The Expert Team Behind the Innovation
Gomes collaborates with luminaries: Dr. Divesha Essa (nanomedicine expert), Dr. Nnamdi Ikemefuna Okafor (polymer chemist), Professor Dinesh Naidoo (neurosurgeon), and Professor Yahya Choonara (WADDP Director). Essa stresses: "Clinicians entering research bring practical challenges, designing real-world solutions." Choonara champions early-career investment for patient-relevant therapies.
This synergy exemplifies Wits' strength in higher education, fostering multidisciplinary teams. For career advice, visit how to write a winning academic CV.
Wits Advanced Drug Delivery PlatformPotential Impacts: Transforming Brain Cancer Care in South Africa
Success could elevate GBM survival beyond 18 months, reduce recurrence, and cut costs by minimizing ineffective dosing. In SA, where neurosurgery access is limited (fewer than 100 specialists for 60 million), scalable nanotherapies via CSF delivery could democratize care, integrable into public systems.
- Enhanced precision: 10x tumor drug uptake vs. systemic.
- Fewer side effects: Protect healthy brain, improve QoL.
- Equity boost: Address Africa-specific barriers like late presentation.
- Economic: Lower long-term hospitalization via better outcomes.
Stakeholders—patients, oncologists, policymakers—welcome this. Dr. Essa notes WADDP's patient-centered models simulate clinical realities.
Challenges, Solutions, and Broader Higher Ed Context
Risks include nanoparticle toxicity, scalability, regulatory hurdles (e.g., SAHPRA approval). Solutions: Biocompatible materials, GLP preclinicals, Phase I trials. Wits' ecosystem supports this via innovation hubs.
In South African universities, such scholarships combat brain drain, retaining talent amid funding pressures. Wits leads in research output, with WADDP exemplifying translational excellence. Check South Africa higher ed jobs for similar opportunities.
Future Outlook: From Bench to Bedside
Gomes envisions clinical trials within 5 years, neurosurgery integration for intraoperative delivery. Globally, nanoparticle GBM therapies (e.g., ONC201-loaded NPs) advance; SA contributions via WADDP position Africa centrally.
This scholarship heralds a clinician-scientist renaissance at Wits, promising actionable insights for brain cancer. For professor ratings and career paths, explore Rate My Professor.
Photo by Bhautik Patel on Unsplash
In summary, Michael Gomes's Wits nanoparticle brain cancer therapy research, fueled by the SAMRC scholarship, exemplifies South African higher education's global impact. By conquering the BBB via innovative carriers and glymphatic targeting, it offers hope against glioblastoma. Stay informed on higher ed jobs, university jobs, career advice, and scholarships to fuel your research journey.